The American biotech company Moderna has developed a modified version of its vaccine for use specifically against the South African variant. It is ready to be tested on humans in clinical trials, the group said on Wednesday.
“Moderna has sent doses of its specific vaccine candidate against the variant […] first identified in South Africa at the NIH [instituts nationaux de santé américains, ndlr], for a clinical study, ”the company said in a statement.
“In our fight against Covid-19, we must be vigilant and proactive about the new variants of SARS-CoV-2 that are emerging,” added Stéphane Bancel, the boss of the company. “Moderna is committed to making as many changes to our vaccine as necessary, until the pandemic is under control,” he continued.
The U.S. Medicines Agency said on Monday that manufacturers will not have to go through the long authorization process again for already approved vaccines if they are changed to combat the emergence of new variants of the coronavirus. , which should greatly shorten the process.